• Explore /
  • Poster
  • / Relugolix in combination with abiraterone acetate, apalutamide, or docetaxel in men with advanced prostate cancer (aPC): A phase 1, three-part, open-label, parallel-cohort study.

Relugolix in combination with abiraterone acetate, apalutamide, or docetaxel in men with advanced prostate cancer (aPC): A phase 1, three-part, open-label, parallel-cohort study.

Abstract Video & Slides Poster

Authors

null

Jose De La Cerda

Urology San Antonio, San Antonio, TX

Jose De La Cerda , Elizabeth Migoya , Bruce Brown , Sophia Lu , Fabian Zohren , Ronald F. Tutrone , Curtis Dunshee

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04666129

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr TPS207)

DOI

10.1200/JCO.2022.40.6_suppl.TPS207

Abstract #

TPS207

Poster Bd #

Q7

Abstract Disclosures

Similar Posters

First Author: Sumit Kumar Subudhi

First Author: Jian Guan

First Author: Simon J. Crabb

First Author: Fred Saad